Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
Martin-Loeches I, Timsit JF, Kollef MH, Wunderink RG, Shime N, Nováček M, Kivistik Ü, Réa-Neto Á, Bruno CJ, Huntington JA, Lin G, Jensen EH, Motyl M, Yu B, Gates D, Butterton JR, Rhee EG. Martin-Loeches I, et al. Among authors: gates d. J Antimicrob Chemother. 2022 Mar 31;77(4):1166-1177. doi: 10.1093/jac/dkab494. J Antimicrob Chemother. 2022. PMID: 35022730 Free PMC article. Clinical Trial.
Serious Asthma Outcomes and Asthma Exacerbations with Maintenance on Inhaled Corticosteroid (Mometasone Furoate)/Long-Acting Beta Agonist (Formoterol) Combination Compared to Step Down to Mometasone Monotherapy.
Weinstein CLJ, Ryan N, Zhang X, Shekar T, Gates D, Lane SJ, Agache I, Nathan RA; SPIRO Investigators. Weinstein CLJ, et al. Among authors: gates d. J Allergy Clin Immunol Pract. 2020 May;8(5):1634-1644.e1. doi: 10.1016/j.jaip.2020.01.021. Epub 2020 Jan 23. J Allergy Clin Immunol Pract. 2020. PMID: 31981733 Clinical Trial.
Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.
Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Gates D, Staudinger H. Tashkin DP, et al. Among authors: gates d. Int J Chron Obstruct Pulmon Dis. 2012;7:73-86. doi: 10.2147/COPD.S29444. Epub 2012 Feb 3. Int J Chron Obstruct Pulmon Dis. 2012. PMID: 22334770 Free PMC article. Clinical Trial.
386 results